DEXAMETHASONE SODIUM PHOSPHATE

Post-LOE

dexamethasone sodium phosphate

Merck & Co.

ANDAINJECTIONINJECTABLE

Approved

Jun 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DEXAMETHASONE SODIUM PHOSPHATE (dexamethasone sodium phosphate) by Merck & Co. is clinical pharmacology naturally occurring glucocorticoids, (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Approved for rheumatoid arthritis, rheumatoid arthritis, psoriasis and 9 more indications. First approved in 2018.

Drug data last refreshed 21h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids, (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, including dexamethasone, are primarily used for their potent…

Indications (11)

Rheumatoid arthritis psoriasis

Worked on DEXAMETHASONE SODIUM PHOSPHATE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (2)

NCT02770807Phase 3Completed

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

Started Mar 2017

176 enrolled

Nervous System DiseaseGenetic Syndrome

NCT01255358Phase 2Completed

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients

Started Feb 2011

22 enrolled

Nervous System DisorderGenetic Syndrome